Nomura Holdings
ACRS icon

Nomura Holdings’s Aclaris Therapeutics ACRS Stock Holding History

Nomura Holdings’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,300
Closed -$310K – 1752
2023
Q3 		$310K Buy
+45,300
New +$387K ﹤0.01% 1196

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Nomura Holdings's ACRS Position: Q1 2022 in Review

Nomura Holdings sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 13,068 shares — an estimated $190K sold.

Nomura Holdings first reported a position in ACRS in Q1 2021 and held it in 4 quarters. The position peaked at $6.05M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Nomura Holdings reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Nomura Holdings sold 13,068 Aclaris Therapeutics shares in Q1 2022, an estimated $190K.
  • Nomura Holdings first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 4 quarters.
  • Nomura Holdings's Aclaris Therapeutics position peaked at $6.05M in Q1 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Nomura Holdings's 13F filing for Q1 2022, filed 18 May 2022.